New combo targets gut bacteria to fight advanced colon cancer
NCT ID NCT06356597
First seen Feb 28, 2026 · Last updated May 08, 2026 · Updated 7 times
Summary
This study tests a combination of three drugs (Tislelizumab, Fruquintinib, and Metronidazole) in 33 adults with advanced colorectal cancer that has a high level of a specific gut bacteria called Fusobacterium nucleatum. The goal is to see if this treatment can slow or stop cancer growth. Participants must have already tried at least two prior standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai First People's Hospital
Shanghai, China
-
Shanghai Ninth People's Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.